Laboratory Corp. of America Holdings (NYSE:LH) reached a new 52-week high on Tuesday . The company traded as high as $136.68 and last traded at $136.50, with a volume of 255,687 shares traded. The stock had previously closed at $135.55.

A number of equities research analysts recently weighed in on LH shares. Zacks Investment Research upgraded shares of Laboratory Corp. of America Holdings from a “hold” rating to a “buy” rating and set a $143.00 target price on the stock in a report on Tuesday, May 17th. Credit Suisse Group AG reiterated an “outperform” rating and issued a $143.00 price objective (up previously from $135.00) on shares of Laboratory Corp. of America Holdings in a research note on Thursday, June 9th. Goldman Sachs Group Inc. increased their price objective on shares of Laboratory Corp. of America Holdings to $119.00 in a research note on Wednesday, March 23rd. Robert W. Baird reiterated a “buy” rating on shares of Laboratory Corp. of America Holdings in a research note on Monday, May 16th. Finally, Barclays PLC increased their price objective on shares of Laboratory Corp. of America Holdings from $152.00 to $155.00 and gave the company an “overweight” rating in a research note on Tuesday, April 26th. Six research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $135.50.

The stock has a market capitalization of $13.92 billion and a PE ratio of 23.57. The company’s 50-day moving average is $129.76 and its 200 day moving average is $119.64.

Laboratory Corp. of America Holdings (NYSE:LH) last released its quarterly earnings data on Monday, April 25th. The company reported $2.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.96 by $0.06. The business had revenue of $2.30 billion for the quarter, compared to the consensus estimate of $2.19 billion. Laboratory Corp. of America Holdings’s revenue for the quarter was up 29.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.73 EPS. On average, analysts anticipate that Laboratory Corp. of America Holdings will post $8.79 earnings per share for the current year.

In other news, insider Edward T. Dodson sold 9,392 shares of the stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $126.42, for a total value of $1,187,336.64. Following the sale, the insider now owns 2,717 shares of the company’s stock, valued at $343,483.14. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO David P. King sold 196,400 shares of the stock in a transaction on Monday, June 13th. The shares were sold at an average price of $128.00, for a total transaction of $25,139,200.00. Following the completion of the sale, the chief executive officer now directly owns 271,210 shares in the company, valued at approximately $34,714,880. The disclosure for this sale can be found here.

Several large investors have recently made changes to their positions in the stock. Victory Capital Management Inc. increased its stake in shares of Laboratory Corp. of America Holdings by 20.2% in the fourth quarter. Victory Capital Management Inc. now owns 9,223 shares of the company’s stock valued at $1,140,000 after buying an additional 1,549 shares in the last quarter. Advantus Capital Management Inc increased its stake in shares of Laboratory Corp. of America Holdings by 3.5% in the fourth quarter. Advantus Capital Management Inc now owns 9,796 shares of the company’s stock valued at $1,211,000 after buying an additional 332 shares in the last quarter. Mutual of America Capital Management LLC increased its stake in shares of Laboratory Corp. of America Holdings by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 11,272 shares of the company’s stock valued at $1,394,000 after buying an additional 61 shares in the last quarter. Suntrust Banks Inc. increased its stake in shares of Laboratory Corp. of America Holdings by 17.4% in the fourth quarter. Suntrust Banks Inc. now owns 13,227 shares of the company’s stock valued at $1,633,000 after buying an additional 1,963 shares in the last quarter. Finally, Trexquant Investment LP purchased a new stake in shares of Laboratory Corp. of America Holdings during the fourth quarter valued at $2,040,000.

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.